Physician profile
Saif Ibrahim
NPI 1457617250
$9,094.25
in general payments reported to CMS, 2019-2025
29 companies · $619 in 2025
The $619 reported for 2025 was less than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,601 · 2020: $335 · 2021: $219 · 2022: $1,636 · 2023: $844 · 2024: $1,839 · 2025: $619.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,303.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,302.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic Vascular, INC. | $2,332.13 | 2019 | |
| Medtronic, INC. | $1,465.79 | 2021-2024 | Onyx Frontier, Cobalt Dr Mri Surescan |
| Boston Scientific Corporation | $1,092.06 | 2019-2025 | Lux-Dx Insertable Cardiac Monitor, General - Brady, Latitude Communicator Power Supply |
| Abiomed | $684.24 | 2020-2024 | Impella |
| Astrazeneca Pharmaceuticals LP | $367.91 | 2021-2025 | Wainua, Farxiga |
| Amgen INC. | $348.69 | 2020-2024 | Repatha |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $329.32 | 2019-2024 | Lifevest |
| Shockwave Medical, INC | $309.41 | 2022-2025 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter, Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter, Shockwave Intravascular Lithotripsy (Ivl) System With The Shockwave C2+ Coronary |
| Heartflow, INC. | $253.68 | 2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $243.51 | 2022-2024 | Jardiance |
| Abbott Laboratories | $224.93 | 2019-2025 | Mitraclip, Amplatzer Talisman, Jot Dx |
| Merck Sharp & Dohme LLC | $211.17 | 2021-2024 | Verquvo |
| E.R. Squibb & Sons, L.L.C. | $176.84 | 2019-2025 | Eliquis, Camzyos |
| Novartis Pharmaceuticals Corporation | $159.48 | 2023-2025 | |
| Cardiovascular Systems INC. | $152.98 | 2019 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Artivion, INC. | $150.82 | 2023 | Cardiac Non-Synergraft |
| Janssen Pharmaceuticals, INC | $135.59 | 2021-2024 | Xarelto |
| Edwards Lifesciences Corporation | $115.00 | 2019 | |
| Lexicon Pharmaceuticals, INC. | $58.49 | 2023-2024 | Inpefa |
| Philips North America LLC | $51.27 | 2024 | (Ck7) Extended Holter |
| Cvrx, INC. | $51.02 | 2024-2025 | Barostim Neo System |
| Actelion Pharmaceuticals US, INC. | $36.66 | 2024-2025 | Opsumit |
| Vital Connect, INC | $31.16 | 2022 | |
| Novo Nordisk INC | $21.80 | 2022 | |
| Inspire Medical Systems, INC. | $21.12 | 2025 | Inspire |
| Pfizer INC. | $19.11 | 2022 | |
| Impulse Dynamics (USA) INC. | $17.91 | 2023 | Optimizer |
| Esperion Therapeutics, INC. | $17.32 | 2025 | Nexletol |
| Baxter Healthcare | $14.84 | 2023 | Hillrom - Carnation Ambulatory Monitor |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Saif Ibrahim listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.